Immunomodulatory activities are well documented for galectin-1, which acts as a suppressor of T cell anti-tumor immunity (59), enhances regulatory monocyte/macrophage subsets (60), promotes tolerogenic dendritic cells and in certain scenarios has been shown to trigger damage-associated molecular pattern (DAMP) pathway activation (61). This evidence concerns the gene LGALS1 and neoplasm.